CTOs on the Move

Allied Managed Care

www.alliedmanagedcare.com

 
Allied Managed Care is a Pasadena, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Highgate Manor Ctr For Health

Highgate Manor Ctr For Health is a Dedham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CollaborateMD

CollaborateMD was founded in 1999 to help medical practices and medical billing services thrive in the jungle of ever changing government and insurance payer regulations without having to spend a fortune on software, support, and hardware.

Abundant Nursing Solutions,

Abundant Nursing Solutions is a company that specializes in providing quality care measures, Value Based Purchasing, Star Ratings, and Quality control measures for home health agencies. They offer Medicare certified Quality Assurance coding and complia...

Alana Healthcare

Alana HealthCare, LLC, headquartered in Nashville, Tennessee, is a health solutions company that provides services to individuals with chronic and complex life conditions.

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.